Arbutus Biopharma
	Provider of ribonucleic acid (RNA) interference therapeutics and lipid nanoparticle delivery technology to pharmaceutical partners. The company focuses on the development of internal product candidates that include apolipoprotein B (ApoB) SNALP for the treatment of high cholesterol and polo-like kinase 1 (PLK1) SNALP for the treatment of cancer.
	['', 'RNA interference therapeutics', ' ', 'lipid drug delivery', ' ', 'high cholesterol treatment', ' ', 'therapeutic device', '']
Tacere Therapeutics
	Developer of therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company utilizes gene silencing technology called DNA-directed RNA interference (ddRNAi).
	['', 'Hepatitis C', ' ', 'RNAi therapeutic', ' ', 'RNA interference drug', '']
